Formulation And In Vitro Evaluation Of Atenolol Mucoadhesive Buccal Tablets

Abstract

Background: Atenolol is a widely used beta-blocker for managing hypertension and angina, traditionally administered via oral tablets. However, oral administration often leads to variable bioavailability and frequent dosing. Mucoadhesive buccal tablets offer a potential alternative by providing a controlled release mechanism and improving patient compliance.

Objective: The primary aim of this study was to formulate and evaluate mucoadhesive buccal tablets of Atenolol to enhance drug bioavailability and ensure sustained release.

Methods: Mucoadhesive buccal tablets of Atenolol were formulated using various mucoadhesive polymers, including Chitosan and Carbopol. The tablets were prepared by direct compression. The formulation process was optimized for tablet hardness, drug content uniformity, and mucoadhesive properties. In vitro evaluation included assessments of physical characteristics, mucoadhesive strength, and drug release profile.

Results: The formulated mucoadhesive buccal tablets exhibited desirable physical properties, including appropriate size, shape, and hardness. The in vitro mucoadhesive tests showed significant adhesion strength, ensuring prolonged residence in the buccal cavity. Drug release studies indicated a controlled and sustained release of Atenolol over an extended period, enhancing the potential for improved therapeutic efficacy.

Conclusion: The study successfully developed and evaluated Atenolol mucoadhesive buccal tablets with promising results. The formulation provides a controlled release of Atenolol, potentially improving bioavailability and patient adherence.